SS-31 (Elamipretide) Peptide research-grade
SS-31 (Elamipretide) Peptide
$51.00 $199.00Price range: $51.00 through $199.00 Select options

SS-31 (Elamipretide) Peptide

Price range: $51.00 through $199.00

Research-grade SS-31 (Elamipretide) Peptide for laboratory investigation. For Research Use Only. Not for human use.

For Research Use Only — Not for Human Consumption
Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Checkout

Accepted Payment Methods

For Research Use Only. Not for human use.

SS-31 (Elamipretide) Peptide research-grade

Overview

SS-31 (Elamipretide) Peptide is supplied as a research-grade catalog material for controlled laboratory investigation.

Laboratories choose this item when protocols need clear identification, consistent labeling, and documentation suitable for reproducible experimental workflows.

Catalog packaging and research-use labeling help purchasing and bench teams keep procurement records aligned with the physical vial.

Research Context for SS-31 (Elamipretide) Peptide

Work involving SS-31 (Elamipretide) Peptide typically focuses on in vitro systems, assay development, and mechanistic model studies.

Teams confirm lot details before setup so conditions stay traceable across repeats and collaborative sites.

Published literature can inform starting ranges for related experimental designs. Each laboratory should still validate performance with its own instruments, plates, and detection chemistry.

Pilot runs are useful before committing larger plate sets, especially when detection chemistry or incubation windows are being optimized.

Documented Attributes

Key catalog attributes for this material include:

  • Research-grade material intended for laboratory investigation only
  • Catalog labeling aligned with research procurement channels
  • Suitable for method development and comparative assay workflows
  • Documentation packages available where provided for the listed lot

Laboratory Handling Notes

Receiving and Identity Checks

Before opening a vial of SS-31 (Elamipretide) Peptide, confirm the physical label against the purchase order and packing list.

Retain outer packaging until identity checks are complete, and report damaged seals to purchasing before experimental work continues.

Reconstitution and Aliquoting

Handle this material according to institutional SOPs for weighing, reconstitution, aliquoting, and storage.

Record lot identifiers in laboratory notebooks before reconstitution. Verify solvent compatibility and storage temperature against your validated process.

Prepare assay buffers and consumables before opening the vial to reduce hold time. Keep unused aliquots labeled with date, solvent, and concentration for later repeats.

Chain of Custody

Keep chain-of-custody notes with inventory checks when material moves between freezers or benches.

Use dedicated spatulas and clean balances to avoid cross-contamination between catalog items. Schedule thaw cycles intentionally rather than repeated freeze-thaw of the same aliquot.

Secondary containment trays reduce spill risk during multi-step reconstitution. Cold-chain interruptions should be noted even when the vial remains sealed.

Why Laboratories Source SS-31 (Elamipretide) Peptide

Procurement and research teams often select this catalog item because it supports:

  • Clear research-use labeling for compliance-aligned purchasing
  • Consistent product identification across multi-lot studies
  • Fit for reference, screening, and mechanistic laboratory models
  • Straightforward catalog support for planning and documentation

Study Planning and Quality Documentation

Before starting experimental work with SS-31 (Elamipretide) Peptide, review any COA or quality files provided with the shipment.

Align your protocol with institutional research requirements and keep use within the labeled research context.

File catalog documentation with the study records at receipt. These steps help keep experiments comparable over time when using SS-31 (Elamipretide) Peptide in sequential study phases.

Method Development Tips

Method development often begins with small pilot plates before larger screening panels.

Document buffer lots, incubation times, and detection settings alongside the material lot number.

If results diverge from historical baselines, re-check reconstitution volume and storage history first. Shared equipment logs help explain variance when multiple operators run the same protocol.

Inventory and Training

Update digital inventory immediately after opening a new lot of SS-31 (Elamipretide) Peptide.

Training new staff on labeling conventions reduces mix-ups across similar catalog SKUs. When transferring methods between sites, share both the written SOP and the lot metadata package.

Dispose of residual solutions according to institutional chemical hygiene rules. Do not repurpose research materials for any non-laboratory application.

Periodic inventory reconciliation keeps expired or depleted lots from entering active workflows. For related catalog options, browse adjacent research categories on this site after confirming your assay needs.

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease.

Peptide Research

For Research Use Only. Not for human use.

PubMed (NIH/NLM) records related to this compound for laboratory literature review. Inclusion does not imply suitability for any use beyond controlled research. Each note below is a research-framed summary using compliance-safe wording.

Showing 147 PubMed records. Displaying 10 per page.

  1. Zhao W et al. (2019). Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory… [PMID: 31747905]

    Laboratory literature summary: Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  2. Zheng H et al. (2025). SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via… [PMID: 39848110]

    Laboratory literature summary: SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  3. Zhu Y et al. (2022). SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease [PMID: 35707274]

    Laboratory literature summary: SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  4. Liu X et al. (2024). Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38… [PMID: 38521160]

    Laboratory literature summary: Mitochondria-targeting peptide SS-31 attenuates ferroptosis via inhibition of the p38 MAPK signaling pathway in the hippocampus of…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  5. Jiang T et al. (2026). SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis… [PMID: 41136322]

    Laboratory literature summary: SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  6. Chavez JD et al. (2020). Mitochondrial protein interaction landscape of SS-31 [PMID: 32554501]

    Laboratory literature summary: Mitochondrial protein interaction landscape of SS-31. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  7. Du X et al. (2024). Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in… [PMID: 38237649]

    Laboratory literature summary: Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  8. Xie L et al. (2026). Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence [PMID: 42456009]

    Laboratory literature summary: Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  9. Xie M et al. (2026). Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on… [PMID: 41801306]

    Laboratory literature summary: Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  10. Russo S et al. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin… [PMID: 36400945]

    Laboratory literature summary: Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  11. Mo Y et al. (2024). SS-31 inhibits the inflammatory response by increasing ATG5 and promoting autophagy in… [PMID: 38581954]

    Laboratory literature summary: SS-31 inhibits the inflammatory response by increasing ATG5 and promoting autophagy in lipopolysaccharide-stimulated HepG2 cells. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  12. Ravenscraft B et al. (2025). Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects… [PMID: 40244206]

    Laboratory literature summary: Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  13. Zhong L et al. (2023). SS-31 Improves Cognitive Function in Sepsis-Associated Encephalopathy by Inhibiting… [PMID: 36333543]

    Laboratory literature summary: SS-31 Improves Cognitive Function in Sepsis-Associated Encephalopathy by Inhibiting the Drp1-NLRP3 Inflammasome Activation. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  14. Ding XW et al. (2021). Laboratory research record on SS-31 (Elamipretide) [PMID: 34302976]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  15. Sweetwyne MT et al. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of… [PMID: 28063595]

    Laboratory literature summary: The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  16. Whitson JA et al. (2020). SS-31 and NMN: Two paths to improve metabolism and function in aged hearts [PMID: 32779818]

    Laboratory literature summary: SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  17. Wu X et al. (2019). Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat… [PMID: 30811524]

    Laboratory literature summary: Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  18. Zhang X et al. (2022). Evaluation of SS-31 as a Potential Strategy for Tendinopathy investigation: An In… [PMID: 35862638]

    Laboratory literature summary: Evaluation of SS-31 as a Potential Strategy for Tendinopathy investigation: An In Vitro Model. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  19. Shan Z et al. (2023). SS-31 alleviated nociceptive responses and restored mitochondrial function in a… [PMID: 37271805]

    Laboratory literature summary: SS-31 alleviated nociceptive responses and restored mitochondrial function in a headache mouse model via Sirt3/Pgc-1α positive feedback loop. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  20. Mo Y et al. (2019). SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1… [PMID: 31582222]

    Laboratory literature summary: SS-31 reduces inflammation and oxidative stress through the inhibition of Fis1 expression in lipopolysaccharide-stimulated microglia. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  21. Patai R et al. (2025). Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical… [PMID: 40169521]

    Laboratory literature summary: Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  22. Li G et al. (2016). Protective Effects of Antioxidant Peptide SS-31 Against Multiple Organ Dysfunctions… [PMID: 26231114]

    Laboratory literature summary: Protective Effects of Antioxidant Peptide SS-31 Against Multiple Organ Dysfunctions During Endotoxemia. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  23. Graham ZA et al. (2022). SS-31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion… [PMID: 35611788]

    Laboratory literature summary: SS-31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young research models mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  24. Yang SK et al. (2020). Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury… [PMID: 32717631]

    Laboratory literature summary: Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  25. Cai J et al. (2018). Protective effects of mitochondrion-targeted peptide SS-31 against hind limb… [PMID: 29589186]

    Laboratory literature summary: Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  26. Pharaoh G et al. (2023). The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in… [PMID: 37462785]

    Laboratory literature summary: The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  27. Ye P et al. (2024). SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette… [PMID: 39069114]

    Laboratory literature summary: SS-31 mitigates oxidative stress and restores mitochondrial function in cigarette smoke-damaged oral epithelial cells via PINK1-mediated…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  28. Nie Y et al. (2023). Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the… [PMID: 38136142]

    Laboratory literature summary: Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  29. Ji Y et al. (2024). SS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in… [PMID: 38411634]

    Laboratory literature summary: SS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in aged mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  30. Xiong L et al. (2024). Laboratory research record on SS-31 (Elamipretide) [PMID: 39364755]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  31. Shang L et al. (2021). SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage… [PMID: 33986918]

    Laboratory literature summary: SS-31 Protects Liver from Ischemia-Reperfusion Injury via Modulating Macrophage Polarization. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  32. Hou Y et al. (2016). Laboratory research record on SS-31 (Elamipretide) [PMID: 26719366]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  33. Yang DQ et al. (2021). Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative… [PMID: 34221235]

    Laboratory literature summary: Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  34. Russo S et al. (2024). SS-31 investigation ameliorates cardiac mitochondrial morphology and defective… [PMID: 38871974]

    Laboratory literature summary: SS-31 investigation ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  35. Whitson JA et al. (2021). Elamipretide (SS-31) investigation attenuates age-associated post-translational… [PMID: 34480713]

    Laboratory literature summary: Elamipretide (SS-31) investigation attenuates age-associated post-translational modifications of heart proteins. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  36. Lu Q et al. (2024). SS-31 modification alleviates ferroptosis induced by superparamagnetic iron oxide… [PMID: 39506934]

    Laboratory literature summary: SS-31 modification alleviates ferroptosis induced by superparamagnetic iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  37. Zhang J et al. (2021). Role of AQP3 in the Vascular Leakage of Sepsis and the Protective Effect of Ss-31 [PMID: 34050090]

    Laboratory literature summary: Role of AQP3 in the Vascular Leakage of Sepsis and the Protective Effect of Ss-31. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  38. Zhang X et al. (2022). SS-31 as a Mitochondrial Protectant in the investigation of Tendinopathy: Evaluation… [PMID: 35984013]

    Laboratory literature summary: SS-31 as a Mitochondrial Protectant in the investigation of Tendinopathy: Evaluation in a Murine Supraspinatus Tendinopathy Model. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  39. Lu HI et al. (2016). Administration of antioxidant peptide SS-31 attenuates transverse aortic… [PMID: 27063219]

    Laboratory literature summary: Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  40. Li M et al. (2024). Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH(2)) derivatives as potent… [PMID: 39301232]

    Laboratory literature summary: Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH(2)) derivatives as potent agents to ameliorate inflammation and increase…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  41. Machiraju P et al. (2019). SS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From… [PMID: 31803760]

    Laboratory literature summary: SS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From research subjects With DCMA, a Mitochondrial…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  42. Mitchell W et al. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface… [PMID: 32273339]

    Laboratory literature summary: The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  43. Liu Y et al. (2021). SS-31 observed endpoints in a mouse model of Friedreich ataxia by upregulation of… [PMID: 34387346]

    Laboratory literature summary: SS-31 observed endpoints in a mouse model of Friedreich ataxia by upregulation of frataxin expression. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  44. Campbell MD et al. (2019). Improving mitochondrial function with SS-31 reverses age-related redox stress and… [PMID: 30597195]

    Laboratory literature summary: Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  45. Stefaniak E et al. (2026). Investigational Peptide SS-31 Modulates Membrane Binding and Aggregation of… [PMID: 42219795]

    Laboratory literature summary: investigational Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  46. Song Z et al. (2026). Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and… [PMID: 42082001]

    Laboratory literature summary: Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  47. Sun M et al. (2021). [Protective effect of mitochondria-targeted antioxidant peptide SS-31 in… [PMID: 35131006]

    Laboratory literature summary: [Protective effect of mitochondria-targeted antioxidant peptide SS-31 in sepsis-induced acute kidney injury]. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  48. Gu Q et al. (2025). SS-31: A promising investigational agent against bleomycin-induced pulmonary fibrosis… [PMID: 40299935]

    Laboratory literature summary: SS-31: A promising investigational agent against bleomycin-induced pulmonary fibrosis in Mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  49. Liu L et al. (2024). Mitochondria-targeted reactive oxygen species blockor SS-31 blocks hepatic stellate… [PMID: 38430023]

    Laboratory literature summary: Mitochondria-targeted reactive oxygen species blockor SS-31 blocks hepatic stellate cell activation and alleviates hepatic fibrosis by…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  50. Zhu Y et al. (2018). SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic… [PMID: 30224944]

    Laboratory literature summary: SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  51. Kuang X et al. (2017). SS-31 peptide enables mitochondrial targeting drug delivery: a promising… [PMID: 29214897]

    Laboratory literature summary: SS-31 peptide enables mitochondrial targeting drug delivery: a promising investigational alteration to prevent hair cell damage from…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  52. Liu D et al. (2019). Enhanced efficiency of mitochondria-targeted peptide SS-31 for acute kidney injury by… [PMID: 31085359]

    Laboratory literature summary: Enhanced efficiency of mitochondria-targeted peptide SS-31 for acute kidney injury by pH-responsive and AKI-kidney targeted nanopolyplexes. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  53. Zhao H et al. (2017). Peptide SS-31 upregulates frataxin expression and improves the quality of… [PMID: 28852135]

    Laboratory literature summary: Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the investigation of Friedreich…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  54. Whitson JA et al. (2022). Age-related disruption of the proteome and acetylome in mouse hearts is associated… [PMID: 35416576]

    Laboratory literature summary: Age-related disruption of the proteome and acetylome in mouse hearts is associated with loss of function and attenuated by elamipretide…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  55. Escribano-Lopez I et al. (2018). Laboratory research record on SS-31 (Elamipretide) [PMID: 30367115]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  56. Zhang M et al. (2017). Chronic administration of mitochondrion-targeted peptide SS-31 prevents… [PMID: 28961281]

    Laboratory literature summary: Chronic administration of mitochondrion-targeted peptide SS-31 prevents atherosclerotic development in ApoE knockout mice fed Western diet. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  57. Yang Q et al. (2026). Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination research… [PMID: 42443448]

    Laboratory literature summary: Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination research protocol Targets TREM2 to Mitigate Post-ischemic Brain…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  58. Hao S et al. (2015). Mitochondrion-Targeted Peptide SS-31 Inhibited Oxidized Low-Density… [PMID: 26633327]

    Laboratory literature summary: Mitochondrion-Targeted Peptide SS-31 Inhibited Oxidized Low-Density Lipoproteins-Induced Foam Cell Formation through both ROS Scavenging…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  59. Graham ZA et al. (2021). A 50 kdyne contusion spinal cord injury with or without the drug SS-31 was not… [PMID: 33611851]

    Laboratory literature summary: A 50 kdyne contusion spinal cord injury with or without the drug SS-31 was not associated with major changes in muscle mass or gene…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  60. Peng X et al. (2021). The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis… [PMID: 34903138]

    Laboratory literature summary: The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells via…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  61. Lightfoot AP et al. (2015). SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes [PMID: 26291279]

    Laboratory literature summary: SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  62. Zhang W et al. (2019). Increased Survival Time With SS-31 After Prolonged Cardiac Arrest in Rats [PMID: 29503242]

    Laboratory literature summary: Increased Survival Time With SS-31 After Prolonged Cardiac Arrest in Rats. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  63. Birk AV et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by… [PMID: 23813215]

    Laboratory literature summary: The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  64. Czigler A et al. (2019). Hypertension Exacerbates Cerebrovascular Oxidative Stress Induced by Mild Traumatic… [PMID: 31266393]

    Laboratory literature summary: Hypertension Exacerbates Cerebrovascular Oxidative Stress Induced by Mild Traumatic Brain Injury: Protective Effects of the…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  65. Kan MH et al. (2025). Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive… [PMID: 41247543]

    Laboratory literature summary: Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive Impairment in Aged Rats: Protective Role of SS-31. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  66. Thomas DA et al. (2007). Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial… [PMID: 17151329]

    Laboratory literature summary: Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  67. Wu Y et al. (2021). SS-31 ameliorates hepatic injury in rats subjected to severe burns plus delayed… [PMID: 33582556]

    Laboratory literature summary: SS-31 ameliorates hepatic injury in rats subjected to severe burns plus delayed resuscitation via inhibiting the mtDNA/STING pathway in…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  68. Wyss JC et al. (2019). Differential Effects of the Mitochondria-Active Tetrapeptide SS-31… [PMID: 31780923]

    Laboratory literature summary: Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH(2)) and Its Peptidase-Targeted Prodrugs…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  69. Tarantini S et al. (2018). Investigation with the mitochondrial-targeted antioxidant peptide SS-31 rescues… [PMID: 29405550]

    Laboratory literature summary: investigation with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  70. Zhao H et al. (2017). Role of mitochondrial dysfunction in renal fibrosis promoted by hypochlorite-modified… [PMID: 28322835]

    Laboratory literature summary: Role of mitochondrial dysfunction in renal fibrosis promoted by hypochlorite-modified albumin in a remnant kidney model and protective…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  71. Hou S et al. (2018). Novel SS-31 modified liposomes for improved protective observed endpoints of… [PMID: 29740652]

    Laboratory literature summary: Novel SS-31 modified liposomes for improved protective observed endpoints of minocycline against drug-induced hearing loss. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  72. Pang Y et al. (2015). Mitochondria-Targeted Antioxidant SS-31 is a Potential Novel Ophthalmic Medication for… [PMID: 27350953]

    Laboratory literature summary: Mitochondria-Targeted Antioxidant SS-31 is a Potential Novel Ophthalmic Medication for Neuroprotection in Glaucoma. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  73. Wu J et al. (2016). BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced… [PMID: 26944333]

    Laboratory literature summary: BDNF pathway is involved in the protective effects of SS-31 on isoflurane-induced cognitive deficits in aging mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  74. Imai T et al. (2017). Protective Effect of Bendavia (SS-31) Against Oxygen/Glucose-Deprivation… [PMID: 27855593]

    Laboratory literature summary: Protective Effect of Bendavia (SS-31) Against Oxygen/Glucose-Deprivation Stress-Induced Mitochondrial Damage in research subjects Brain…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  75. Tung C et al. (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and investigational… [PMID: 39940712]

    Laboratory literature summary: Elamipretide: A Review of Its Structure, Mechanism of Action, and investigational Potential. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  76. Karaa A et al. (2023). Laboratory research record on SS-31 (Elamipretide) [PMID: 37268435]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  77. Shirley M (2026). Elamipretide: First Approval [PMID: 41335372]

    Laboratory literature summary: Elamipretide: First Approval. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  78. Author et al. (2026). Elamipretide Hydrochloride [PMID: 41206662]

    Laboratory literature summary: Elamipretide Hydrochloride. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  79. Karaa A et al. (2024). Genotype-specific effects of elamipretide in research subjects with primary… [PMID: 39574155]

    Laboratory literature summary: Genotype-specific effects of elamipretide in research subjects with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  80. Thompson WR et al. (2024). Long-term observed endpoints and laboratory profile of elamipretide in research… [PMID: 38602181]

    Laboratory literature summary: Long-term observed endpoints and laboratory profile of elamipretide in research subjects with Barth syndrome: 168-week open-label…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  81. Obi C et al. (2022). Targeting mitochondrial dysfunction with elamipretide [PMID: 35037146]

    Laboratory literature summary: Targeting mitochondrial dysfunction with elamipretide. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  82. Sabbah HN (2022). Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid [PMID: 34623544]

    Laboratory literature summary: Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  83. Sabbah HN et al. (2025). Contemporary insights into elamipretide's mitochondrial mechanism of action and… [PMID: 40294492]

    Laboratory literature summary: Contemporary insights into elamipretide's mitochondrial mechanism of action and investigational effects. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  84. Zhang H et al. (2023). Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting… [PMID: 36609266]

    Laboratory literature summary: Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  85. Nhu NT et al. (2021). Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide… [PMID: 35111001]

    Laboratory literature summary: Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  86. Patel N et al. (2023). Elamipretide mitigates ischemia-reperfusion injury in a swine model of hemorrhagic shock [PMID: 36934127]

    Laboratory literature summary: Elamipretide mitigates ischemia-reperfusion injury in a swine model of hemorrhagic shock. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  87. Hornby B et al. (2022). Natural history comparison study to assess the observed endpoints of elamipretide in… [PMID: 36056411]

    Laboratory literature summary: Natural history comparison study to assess the observed endpoints of elamipretide in research subjects with Barth syndrome. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  88. Jacob N et al. (2025). Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report [PMID: 40816230]

    Laboratory literature summary: Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  89. Vieira Neto E et al. (2026). Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional… [PMID: 41500837]

    Laboratory literature summary: Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and research subjects Fibroblasts. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  90. Karanjia R et al. (2024). Laboratory research record on SS-31 (Elamipretide) [PMID: 37923251]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  91. Petcherski A et al. (2018). Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by… [PMID: 30389435]

    Laboratory literature summary: Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  92. Zhao C et al. (2026). Laboratory research record on SS-31 (Elamipretide) [PMID: 41260682]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  93. Van den Eynde J et al. (2023). Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for… [PMID: 37041653]

    Laboratory literature summary: Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  94. Ehlers JP et al. (2025). Laboratory research record on SS-31 (Elamipretide) [PMID: 39605874]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  95. Sabbah HN (2021). Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide [PMID: 33001359]

    Laboratory literature summary: Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  96. Bai H et al. (2020). Elamipretide as a potential candidate for relieving cryodamage to research subjects… [PMID: 32240641]

    Laboratory literature summary: Elamipretide as a potential candidate for relieving cryodamage to research subjects spermatozoa during cryopreservation. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  97. Daneshgar N et al. (2022). Laboratory research record on SS-31 (Elamipretide) [PMID: 34953771]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  98. Sabbah HN et al. (2023). Temporal evolution of the heart failure phenotype in Barth syndrome and investigation… [PMID: 37325898]

    Laboratory literature summary: Temporal evolution of the heart failure phenotype in Barth syndrome and investigation with elamipretide. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  99. Nguyen ST et al. (2025). Mitochondrial-Targeted Protective Potential of Elamipretide for the In Vitro… [PMID: 40941292]

    Laboratory literature summary: Mitochondrial-Targeted Protective Potential of Elamipretide for the In Vitro Production of Porcine Embryos. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  100. Campbell MD et al. (2022). Elamipretide effects on the skeletal muscle phosphoproteome in aged research models mice [PMID: 36322234]

    Laboratory literature summary: Elamipretide effects on the skeletal muscle phosphoproteome in aged research models mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  101. Jiang W et al. (2023). Elamipretide reduces pyroptosis and improves functional recovery after spinal cord injury [PMID: 37081763]

    Laboratory literature summary: Elamipretide reduces pyroptosis and improves functional recovery after spinal cord injury. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  102. Mitchell W et al. (2025). The Mitochondria-Targeted Peptide investigational Elamipretide Improves Cardiac and… [PMID: 40080911]

    Laboratory literature summary: The Mitochondria-Targeted Peptide investigational Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  103. Allen ME et al. (2020). The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae… [PMID: 32680996]

    Laboratory literature summary: The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  104. Campbell MD et al. (2023). Intermittent investigation with elamipretide preserves exercise tolerance in aged… [PMID: 36840897]

    Laboratory literature summary: Intermittent investigation with elamipretide preserves exercise tolerance in aged research models mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  105. Karaa A et al. (2020). Laboratory research record on SS-31 (Elamipretide) [PMID: 32096613]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  106. Karaa A et al. (2018). Laboratory research record on SS-31 (Elamipretide) [PMID: 29500292]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  107. Tse BC et al. (2020). Mitochondrial targeted research protocol with elamipretide (MTP-131) as an adjunct to… [PMID: 32758490]

    Laboratory literature summary: Mitochondrial targeted research protocol with elamipretide (MTP-131) as an adjunct to oncology research models necrosis factor…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  108. Vahle B et al. (2026). Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle… [PMID: 42290373]

    Laboratory literature summary: Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  109. Zuo Y et al. (2020). Elamipretide Attenuates Pyroptosis and Perioperative Neurocognitive Disorders in Aged Mice [PMID: 32903868]

    Laboratory literature summary: Elamipretide Attenuates Pyroptosis and Perioperative Neurocognitive Disorders in Aged Mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  110. Grosser JA et al. (2021). The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment… [PMID: 34022923]

    Laboratory literature summary: The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  111. Chatfield KC et al. (2019). Elamipretide Improves Mitochondrial Function in the Failing research subjects Heart [PMID: 31061916]

    Laboratory literature summary: Elamipretide Improves Mitochondrial Function in the Failing research subjects Heart. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  112. Villatore A et al. (2026). Elamipretide: a mitochondria-targeting drug for Barth syndrome [PMID: 42448476]

    Laboratory literature summary: Elamipretide: a mitochondria-targeting drug for Barth syndrome. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  113. Hong S et al. (2022). Effects of Elamipretide on Autophagy in Renal Cells of Pigs with Metabolic Syndrome [PMID: 36139466]

    Laboratory literature summary: Effects of Elamipretide on Autophagy in Renal Cells of Pigs with Metabolic Syndrome. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  114. Kowalczyk A et al. (2021). Antioxidant effect of Elamipretide on bull's sperm cells during freezing/thawing process [PMID: 33675580]

    Laboratory literature summary: Antioxidant effect of Elamipretide on bull's sperm cells during freezing/thawing process. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  115. Reid Thompson W et al. (2021). Laboratory research record on SS-31 (Elamipretide) [PMID: 33077895]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  116. Nickel K et al. (2022). Long-term investigation with Elamipretide enhances healthy aging phenotypes in mice [PMID: 36250163]

    Laboratory literature summary: Long-term investigation with Elamipretide enhances healthy aging phenotypes in mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  117. Mettu PS et al. (2022). Phase 1 laboratory Trial of Elamipretide in Dry Age-Related Macular Degeneration and… [PMID: 36246181]

    Laboratory literature summary: Phase 1 laboratory Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  118. Allingham MJ et al. (2022). Phase 1 laboratory Trial of Elamipretide in Intermediate Age-Related Macular… [PMID: 36246187]

    Laboratory literature summary: Phase 1 laboratory Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  119. Goldstein AC et al. (2024). Expanded-access use of elamipretide in a critically ill research subjects with Barth… [PMID: 39669625]

    Laboratory literature summary: Expanded-access use of elamipretide in a critically ill research subjects with Barth syndrome. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  120. Zhang YM et al. (2024). Mitochondrial antioxidant elamipretide improves learning and memory impairment induced… [PMID: 38688894]

    Laboratory literature summary: Mitochondrial antioxidant elamipretide improves learning and memory impairment induced by chronic sleep deprivation in mice. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  121. Koenig MK et al. (2023). Use of Elamipretide in research subjects assigned investigation in the compassionate… [PMID: 36636586]

    Laboratory literature summary: Use of Elamipretide in research subjects assigned investigation in the compassionate use program: Case series in pediatric research…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  122. Huang HL et al. (2024). Megalin-targeting and ROS-responsive elamipretide-conjugated polymeric prodrug for… [PMID: 38805970]

    Laboratory literature summary: Megalin-targeting and ROS-responsive elamipretide-conjugated polymeric prodrug for investigation of acute kidney injury. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  123. Yao X et al. (2024). Effect of Elamipretide on the Vitrification of Mouse Ovarian Tissue by Freezing [PMID: 38648553]

    Laboratory literature summary: Effect of Elamipretide on the Vitrification of Mouse Ovarian Tissue by Freezing. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  124. Pharaoh G et al. (2023). Elamipretide Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake… [PMID: 36778398]

    Laboratory literature summary: Elamipretide Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake through the Adenine Nucleotide Translocator (ANT). Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  125. Butler J et al. (2020). Effects of Elamipretide on Left Ventricular Function in research subjects With Heart… [PMID: 32068002]

    Laboratory literature summary: Effects of Elamipretide on Left Ventricular Function in research subjects With Heart Failure With Reduced Ejection Fraction: The…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  126. Wu J et al. (2017). Elamipretide (SS-31) Ameliorates Isoflurane-Induced Long-Term Impairments of… [PMID: 28487636]

    Laboratory literature summary: Elamipretide (SS-31) Ameliorates Isoflurane-Induced Long-Term Impairments of Mitochondrial Morphogenesis and Cognition in Developing Rats. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  127. Sabbah HN et al. (2016). Chronic research protocol With Elamipretide (MTP-131), a Novel Mitochondria-Targeting… [PMID: 26839394]

    Laboratory literature summary: Chronic research protocol With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  128. Ortmann L et al. (2025). Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report [PMID: 39917770]

    Laboratory literature summary: Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  129. Sabbah HN et al. (2019). Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart… [PMID: 30688415]

    Laboratory literature summary: Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  130. Daubert MA et al. (2017). Laboratory research record on SS-31 (Elamipretide) [PMID: 29217757]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  131. Bulbul O et al. (2025). Effect of elamipretide and methylprednisolone investigation on optic nerve, retina and… [PMID: 39601106]

    Laboratory literature summary: Effect of elamipretide and methylprednisolone investigation on optic nerve, retina and brain damage in a methanol poisoning model:…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  132. Patino J et al. (2024). Expanded-access use of elamipretide in a research subjects with membrane… [PMID: 38919884]

    Laboratory literature summary: Expanded-access use of elamipretide in a research subjects with membrane protein-associated neurodegeneration. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  133. Yao S et al. (2024). Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR… [PMID: 37981044]

    Laboratory literature summary: Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR analytical assessment and antioxidant research…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  134. Di K et al. (2026). Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains… [PMID: 42291734]

    Laboratory literature summary: Cardiolipin remodelling in mitochondrial therapeutics: translational evidence chains from elamipretide to emerging strategies. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  135. Ansari S et al. (2024). Laboratory research record on SS-31 (Elamipretide) [PMID: 39619320]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  136. Saad A et al. (2017). Phase 2a laboratory Trial of Mitochondrial Protection (Elamipretide) During Stent… [PMID: 28916603]

    Laboratory literature summary: Phase 2a laboratory Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in research subjects With…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  137. Miyamoto S et al. (2020). Laboratory research record on SS-31 (Elamipretide) [PMID: 32277051]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  138. Author et al. (2018). Laboratory research record on SS-31 (Elamipretide) [PMID: 29610236]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  139. Author et al. (2018). Laboratory research record on SS-31 (Elamipretide) [PMID: 30455261]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

  140. Hortmann M et al. (2019). The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in… [PMID: 28534645]

    Laboratory literature summary: The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  141. Amedro P et al. (2026). Elamipretide in pediatric Barth syndrome: from heart failure to school return [PMID: 42415111]

    Laboratory literature summary: Elamipretide in pediatric Barth syndrome: from heart failure to school return. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  142. Mitchell W et al. (2024). The mitochondrial-targeted peptide investigational elamipretide improves cardiac and… [PMID: 39554099]

    Laboratory literature summary: The mitochondrial-targeted peptide investigational elamipretide improves cardiac and skeletal muscle function during aging without…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  143. Liu Y et al. (2021). Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related… [PMID: 33732135]

    Laboratory literature summary: Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related Regions Following Prolonged Neuroinflammation…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  144. Najafi A et al. (2025). Elamipretide enhances post-thaw rooster sperm quality by mitigating oxidative stress… [PMID: 40604246]

    Laboratory literature summary: Elamipretide enhances post-thaw rooster sperm quality by mitigating oxidative stress and optimizing mitochondrial function during…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  145. Schauer A et al. (2026). Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without… [PMID: 41596703]

    Laboratory literature summary: Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  146. Sabbah HN et al. (2018). Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following… [PMID: 29951944]

    Laboratory literature summary: Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term research protocol with Elamipretide. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  147. Roshanravan B et al. (2021). Laboratory research record on SS-31 (Elamipretide) [PMID: 34264994]

    PubMed laboratory record discussing SS-31 (Elamipretide) in a research context. Review the full methods and limitations on PubMed; research use only.

Browse the full PubMed index: PubMed search.

Additional information

Weight .125 lbs
Dimensions 8 × 7 × .5 in
Size: No selection

5 mg, 10 mg, 50 mg

Keep lyophilized peptides sealed in their original vial, protected from light and humidity, and store at -4°F or colder for optimal long-term stability in research settings; short-term refrigeration at around 39°F suffices for immediate use within weeks, though freezer storage maximizes integrity across extended research timelines.

Frequently Asked Questions

What is SS-31 (Elamipretide) peptide?

SS-31, also known as Elamipretide, is a synthetic peptide designed to target mitochondrial-related pathways. It is commonly studied in research laboratories for its interaction with cellular energy and mitochondrial function.

What is SS-31 used for in research?

SS-31 is used in research laboratories to investigate mitochondrial activity, cellular energy processes, and oxidative stress-related pathways. It is not approved for human use.

Is SS-31 (Elamipretide) Peptide approved or intended for human use?

No. SS-31 (Elamipretide) is strictly intended for research purposes only and is not approved by the FDA for human use.

Is SS-31 (Elamipretide) Peptide FDA-approved for medical or clinical use?

No. SS-31 (Elamipretide) is not approved by the U.S. Food and Drug Administration for any medical, therapeutic, or diagnostic use.

In what form is SS-31 supplied?

SS-31 is supplied as a lyophilized (freeze-dried) peptide powder for use in controlled research laboratories.

How should SS-31 be stored?

Store sealed, lyophilized peptides protected from light and humidity at -4°F or colder; refrigeration (~39°F) is suitable for short-term use.

What vial sizes are available for SS-31?

SS-31 is available in multiple vial sizes (e.g., 5000 IU, 10,000 IU).

Is SS-31 (Elamipretide) Peptide sold as a prescription product?

No prescription is required; however, it is sold strictly for research use only.

How is SS-31 shipped?

Orders are processed and shipped using secure, protective packaging to maintain product integrity during transit. For more info, visit: https://www.nationwidepeptides.com/shipping-and-payments/

Can SS-31 be used for mitochondrial or health-related purposes?

SS-31 is studied in research laboratories for mitochondrial-related pathways; however, it is not approved for the diagnosis, experimental regimen, cure, or prevention of any disease or condition.